Laparoscopy May Have Limited Role In Prostate Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

NEW YORK--Initial enthusiasm accompanying the introduction of laparoscopy in the diagnosis and treatment of prostate cancer has given way to a more realistic assessment of its value, R. Ernest Sosa, MD, said at a conference on prostate cancer at Lenox Hill Hospital. It continues to have value, but its role is limited and is unlikely to broaden.

NEW YORK--Initial enthusiasm accompanying the introduction oflaparoscopy in the diagnosis and treatment of prostate cancerhas given way to a more realistic assessment of its value, R.Ernest Sosa, MD, said at a conference on prostate cancer at LenoxHill Hospital. It continues to have value, but its role is limitedand is unlikely to broaden.

Dr. Sosa, associate professor of urology at Cornell UniversityMedical College, praised laparoscopy as a tool in staging as wellas dissection when lymph node metastases have been identified.He cautioned, however, that laparoscopy should be done only whenthere is a high likelihood of node involvement.

In selected patients, laparoscopy offers as advantages shorterhospital stay, lower costs (because of shorter stay), rapid convalescence,and reduced morbidity, compared with conventional surgery. Onthe down side, however, the procedure adds about 2 hours to surgicaltime and requires special expertise, making it a more expensiveoperation to perform.

The key to using laparoscopy effectively, Dr. Sosa said, liesin patient selection. Patients with T1a and T1b disease are notgood candidates because of the lower likelihood of positive nodes.In patients with later stage disease and high Gleason scales,the value of laparoscopy increases.

The complication rate has improved from 15% in 1991 to 6% today,and the time required to perform the procedure has been reduced,he noted.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content